At a glance
- Originator Abbott Laboratories
- Class Antibacterials; Naphthyridines
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 21 May 2001 Profile reviewed but no significant changes made
- 10 Jul 1998 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 01 May 1995 New profile